TOI
Oncology Institute Inc
6.20$
+20.9%
vs. previous close
Closing price · As of: Aug 11, 2026
Filings
Filings
Listed US companies must report material events to the Securities and Exchange Commission. This page lists the filings of Oncology Institute Inc (TOI) with date, type and a link to the original document.
| Date | Type | Filing | Original |
|---|---|---|---|
| 08/21/2026 | Current report (8-K) | Starling Oncology, Inc. (TOI): Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Financial Statements and Exhibits | View report ↗ |
| 08/21/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
| 08/06/2026 | Current report (8-K) | Starling Oncology, Inc. (TOI): Results of Operations and Financial Condition; Financial Statements and Exhibits | View report ↗ |
| 08/03/2026 | Current report (8-K) | Oncology Institute, Inc. (TOI): Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Regulation FD Disclosure; Financial Statements and Exhibits | View report ↗ |
| 07/14/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
| 07/07/2026 | Current report (8-K) | Oncology Institute, Inc. (TOI): Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Unregistered Sales of Equity Securities; Regulation FD Disclosure; Financial Statements and Exhibits | View report ↗ |
Showing the 100 most recent filings of the selected type.
Data as of: August 11, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Filings: SEC EDGAR
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.